New methods for gene therapy and bone marrow transplants in Fanconi anemia
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemia
This study is looking for better ways to help people with Fanconi anemia by using safer treatments that avoid harsh chemotherapy and radiation before they get a bone marrow or stem cell transplant, making the process easier and reducing the chance of future cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10656502 on NIH RePORTER |
What this research studies
This research focuses on improving treatments for Fanconi anemia, a genetic disorder that leads to bone marrow failure and increased cancer risk. The team is exploring nongenotoxic conditioning methods, which avoid harmful chemotherapy and radiation, to prepare patients for bone marrow or stem cell transplants. By using antibody drug conjugates that target specific stem cells, the goal is to enhance the success of transplants while minimizing the risk of secondary cancers. This innovative approach aims to provide safer and more effective treatment options for patients with this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Fanconi anemia who require a bone marrow or stem cell transplant.
Not a fit: Patients with Fanconi anemia who are not candidates for transplantation or those with advanced cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer bone marrow transplants and improved outcomes for patients with Fanconi anemia.
How similar studies have performed: Previous research has shown promise in using antibody drug conjugates for similar applications, indicating potential for success in this novel approach.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Kiem, Hans-Peter — Fred Hutchinson Cancer Center
- Study coordinator: Kiem, Hans-Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.